BioSpace News Archive

West Pharmaceutical Services, Inc. announced its financial results for the fourth-quarter and full-year 2022 and introduced full-year 2023 financial guidance.

Quest Diagnostics, the world’s leading provider of diagnostic information services, and Tower Health, a regional integrated healthcare system in Pennsylvania, are teaming up to enhance the quality and value of diagnostic services to patients and their doctors.

Aera Therapeutics announced its launch with a vision to harness its proprietary delivery platform to unlock the potential of genetic medicines across a wide range of modalities and therapeutic areas.

KalVista Pharmaceuticals, Inc. announced the acceptance of multiple abstracts at the 2023 Annual Scientific Meeting for the American Academy of Allergy, Asthma & Immunology taking place in San Antonio, Texas from February 24-27.

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, announced the first patient has been dosed in the ASPEN-07 study evaluating evorpacept, a next generation CD47 blocker, in combination with PADCEV®, an antibody drug conjugate, in patients with urothelial cancer.

Shattuck Labs, Inc. announced it will report its fourth quarter and full year 2022 financial results and provide a general business overview on Thursday, February 23, 2023.

Decibel Therapeutics announced that Laurence Reid, Ph.D., Chief Executive Officer, will present a corporate overview at the SVB Securities Global Biopharma Conference being held virtually on Thursday, February 16, 2023 at 9:20 a.m. E.T.

EyePoint Pharmaceuticals, Inc. announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2016 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635.

LAVATherapeuticsN.V.(Nasdaq:LVTX), a clinical stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma-delta T cell engagers to transform the treatment of cancer, today announced initial clinical data from its ongoing Phase 1/2a study of LAVA-1207 in patients with therapy refractory metastatic castration resistant prostate cancer (mCRPC).

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced the initiation of Phase 2 clinical trials evaluating the safety and efficacy of ADX‑629, a novel, internally developed, investigational oral RASP modulator, for the treatment of minimal change disease and Sjögren-Larsson Syndrome.